Shenzhen Hepalink Pharmaceutical Group

Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-ß Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada.

The Company has assembled several bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE class that can induce tumor specific immunity and enhance clinical outcome. Several of the lead components have clinical track records and extensive development dossiers that can be exploited to be integral to combinatorial immunooncology treatment strategies.

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.

Labway develops testing services and optimizes resource allocation, becoming a strong support for healthcare institutions in order to help them reduce costs and risks, increase efficiency and patient satisfaction, and promote public healthcare management.

The Company has assembled several bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE class that can induce tumor specific immunity and enhance clinical outcome. Several of the lead components have clinical track records and extensive development dossiers that can be exploited to be integral to combinatorial immunooncology treatment strategies.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Scientific Protein Laboratories LLC engages in manufacturing active pharmaceutical ingredients (APIs) for pharmaceutical, veterinary, and food industries worldwide. It offers heparin products, pancreatic enzyme products, derivative, blends, and custom specifications. The company also provides contract biopharmaceutical development and manufacturing services, including natural products extraction, fermentation and purification, analytical support, and heparin derivatives production. In addition, it supports its clients in various aspects of regulatory compliance, including providing CMC sections of IND, NDA, and aNDA; and offers process validation and equipment qualification services in support of its customers’ regulatory filings. The company was founded in 1976 and is based in Waunakee, Wisconsin.